Sendek Joel 4
4 · Spero Therapeutics, Inc. · Filed Nov 7, 2017
Insider Transaction Report
Form 4
Sendek Joel
Chief Financial Officer
Transactions
- Purchase
Common Stock
2017-11-06$14.00/sh+5,000$70,000→ 15,181 total - Conversion
Common Stock
2017-11-06+10,181→ 10,181 total(indirect: By Trust) - Conversion
Series C Preferred Stock
2017-11-06−61,880→ 0 total(indirect: By Trust)→ Common Stock (10,181 underlying)
Footnotes (2)
- [F1]Amount of underlying securities reflects the application of the applicable conversion ratio as set forth in the Issuer's Amended and Restated Certificate of Incorporation in effect immediately prior to the closing of the initial public offering (as adjusted by the 1-for-6.0774 reverse stock split of the Issuer's common stock effected on October 20, 2017). The preferred stock had no expiration date.
- [F2]Reflects shares that were purchased through a directed share program in connection with the Issuer's initial public offering.